| Literature DB >> 34707637 |
Linya Ma1, Jianjian Zhu1, Jing Wang2, Yazhou Huang1, Jibo Zhang1, Chao Wang1, Yuan Zhou1, Dan Peng1,3.
Abstract
BACKGROUND: Tyrosinase-positive oculocutaneous albinism (OCA, type II, OCA2) is an autosomal recessive genetic disease in which the biosynthesis of melanin decreases in the skin, hair, and eyes. OCA2 disease is caused by mutations in OCA2 gene. The gene product plays a role in regulating the pH of melanosomes. Up to now, hundreds of OCA2 mutations have been reported and novel variants are still being discovered.Entities:
Keywords: OCA2 gene; missense variants; next-generation sequencing; novel variants; oculocutaneous albinism
Year: 2021 PMID: 34707637 PMCID: PMC8544823 DOI: 10.3389/fgene.2021.715437
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Clinical characteristics and genotypes of the 28 patients.
| Patient ID | Gender | Age | Molecular diagnosis | Mutations | |||
|
|
|
|
| ||||
| 1 | M | 25 | OCA2 | c.1178G > T | Ma | c.1178G > T | Pa |
| 2 | F | 5 | OCA2 | c.1963dupA | Ma | c.1444A > G | Pa |
| 3 | F | 9 | OCA2 | c.1255C > T | Ma | c.1255C > T | Pa |
| 4 | M | 3 | OCA2 | c.833T > G | NA | c.406C > T | NA |
| 5 | F | 1 | OCA2 | c.1349C > T | NA | c.1349C > T | NA |
| 6 | M | 10 | OCA2 | c.2228C > T | NA | c.593C > T | NA |
| 7 | F | 9 | OCA2 | c.1441G > A | NA | c.2159G > C | NA |
| 8 | F | 14 | OCA2 | c.2344G > A | NA | c.1844A > G | NA |
| 9 | F | 6 | OCA2 | c.406C > T | NA | c.1955G > A | NA |
| 10 | M | 4 | OCA2 | c.1663C > T | NA | c.2330G > A | NA |
| 11 | M | 4 | OCA2 | c.1349C > T | NA | c.1441G > A | NA |
| 12 | M | 24 | OCA2 | c.1255C > T | Ma | c.2180T > C | Pa |
| 13 | F | 5 | OCA2 | c.1182 + 1G > A | NA | c.1405_1406delATinsC | NA |
| 14 | F | 8 | OCA2 | c.1255C > T | NA | c.2323G > C | NA |
| 15 | F | 26 | OCA2 | c.1182 + 1G > A | NA | c.1405_1406delATinsC | NA |
| 16 | F | 25 | OCA2 | c.156delC | NA | c.1441G > A | NA |
| 17 | F | 17 | OCA2 | c.1255C > T | NA | c.1349C > T | NA |
| 18 | F | 3 | OCA2 | c.1255C > T | NA | c.2180T > C | NA |
| 19 | M | 13 | OCA2 | c.163delG | NA | c.1441G > A | NA |
| 20 | F | 22 | OCA2 | c.1441G > A | NA | c.2344G > A | NA |
| 21 | M | 5 | OCA2 | c.808-3C > G | NA | c.1441G > A | NA |
| 22 | M | 21 | OCA2 | c.1951 + 1G > C | NA | c.1423A > G | NA |
| 23 | F | 9 | OCA2 | c.2359G > A | NA | c.1255C > T | NA |
| 24 | M | 2 | OCA2 | c.1363A > G | NA | c.1637-2A > G | NA |
| 25 | F | 7 | OCA2 | c.593C > T | NA | c.2228C > T | NA |
| 26 | M | 4 | OCA2 | c.406C > T | Ma | c.593C > T | Pa |
| 27 | M | 2 | OCA2 | c.2323G > A | Ma | c.830_836dup | Pa |
| 28 | M | 1 | OCA2 | c.944_945insCAC | Ma | c.1139_1141del | Pa |
Summary of OCA2 variants identified in this study.
| Nt change | gDNA change(chr15) | Exon No. | AA change | Function | Minor Allele frequency (gnomAD) | Mutation frequency |
| c.156delC | g.28326865delG | Exon2 | p.R53Gfs*49 | frameshift | 0.00001217 | 1/56 |
| c.163delG | g.28326858delC | Exon2 | p.A55Lfs*47 | frameshift | 0.00001079 | 1/56 |
| c.406C > T | g.28273126G > A | Exon4 | p.R136X | stopgain | 0.00001591 | 3/56 |
| c.593C > T | g.28267700G > A | Exon6 | p.P198L | missense | 0.0001238 | 3/56 |
| c.808-3C > G | g.28261332-3G > C | Intron7 | – | splicing | 0.000003977 | 1/56 |
| c.833T > G | g.28261307A > C | Exon8 | p.L278X | frameshift | – | 1/56 |
| c.830_836dup | g.28261304_g.28261310dup | Exon8 | p.N279Kfs*17 | frameshift | – | 1/56 |
| c.944_945insCAC | g.28260021_g.28260022insGTG | Exon9 | p.P315LinsT | insertion | – | 1/56 |
| c.1139_1141del | g.28234788_g.28234790delCCA | Exon11 | p.V380del | deletion | – | 1/56 |
| c.1178G > T | g.28234751C > A | Exon11 | p.G393V | missense | 0.000003979 | 1/56 |
| c.1182 + 1G > A | g.28230320 + 1C > T | Intron11 | – | splicing | – | 2/56 |
| c.1255C > T | g.28230319G > A | Exon13 | p.R419W | missense | 0.0002659 | 6/56 |
| c.1349C > T | g.28230225G > A | Exon13 | p.T450M | missense | 0.00001776 | 3/56 |
| c.1363A > G | g.28230211T > C | Exon13 | p.R455G | missense | 0.0002453 | 1/56 |
| c.1405_1406delATinsC | g.28228588_g.28228589delinsG | Exon14 | p.I469Lfs*4 | frameshift | – | 2/56 |
| c.1423A > G | g.28228571T > C | Exon14 | p.T475A | missense | – | 1/56 |
| c.1441G > A | g.28228553C > T | Exon14 | p.A481T | missense | 0.008427 | 6/56 |
| c.1444A > G | g.28228550T > C | Exon14 | p.T482A | missense | – | 1/56 |
| c.1637-2A > G | g.28202881-2T > C | Intron15 | – | splicing | – | 1/56 |
| c.1663C > T | g.28202855G > A | Exon16 | p.R555C | missense | 0.0001186 | 1/56 |
| c.1844A > G | g.28197037T > C | Exon18 | p.H615R | missense | 0.04345 | 1/56 |
| c.1951 + 1G > C | g.28196930 + 1C > G | Intron18 | – | splicing | 0.000003984 | 1/56 |
| c.1955G > A | g.28171397C > 7 | Exon19 | p.W652X | stopgain | – | 1/56 |
| c.1963dupA | g.28171390dupT | Exon14 | p.I655Nfs*12 | frameshift | – | 1/56 |
| c.2159G > C | g.28116385C > G | Exon21 | p.R720P | missense | – | 1/56 |
| c.2180T > C | g.28116364A > G | Exon21 | p.L727P | missense | – | 2/56 |
| c.2228C > T | g.28116316G > A | Exon21 | p.P743L | missense | 0.0001344 | 2/56 |
| c.2323G > A | g.28096543C > T | Exon22 | p.G775S | missense | 0.000008028 | 2/56 |
| c.2330G > A | g.28096536C > T | Exon22 | p.C777Y | missense | 0.00003277 | 1/56 |
| c.2344G > A | g.28090193C > T | Exon23 | p.G782R | missense | 0.000007071 | 2/56 |
| c.2359G > A | g.28090178C > T | Exon23 | p.A787T | missense | 0.00004374 | 1/56 |
FIGURE 1Variants pattern of OCA2. Loss-of-function variants are labeled above the diagram. Missense variants are labeled below the diagram. Purple region represents P-permease domain. * represents the novel variants.
FIGURE 2Novel missense variants of OCA2. (A) Conservation analysis of OCA2 missense variants. (B) Simulation of the amino acids conformation changes by I-TASSER.
Pathogenicity analysis of novel variants.
| Nt change | AA change | SIFT | Polyphen2 | Mutation assessor | PROVEAN | CADD score | Variant classification | Evidence criterion |
| c.156delC | p.R53Gfs*49 | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.830_836dup | p.N279Kfs*17 | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.1405_1406delATinsC | p.I469Lfs*4 | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.1963dupA | p.I655Nfs*12 | – | – | – | – | – | Likely pathogenic | PVS1 + PM2 |
| c.1637-2A > G | c.1637-2A > G | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.1951 + 1G > C | c.1951 + 1G > C | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.833T > G | p.Leu278X | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP4 |
| c.1955G > A | p.W652X | – | – | – | – | – | Pathogenic | PVS1 + PM2 + PP3 |
| c.944_945insCAC | p.P315LinsT | – | – | – | D | – | Uncertain significance | PM2 + PP3 |
| c.1178G > T | p.G393V | D | PD | High | D | 33 | Uncertain significance | PM2 + PP3 |
| c.1444A > G | p.T482A | D | PD | High | D | 25.5 | Uncertain significance | PM2 + PM3 + PP3 |
| c.2159G > C | p.R720P | D | PD | Medium | D | 33 | Uncertain significance | PM2 + PP3 |